SIRT1 and cancer: We used the SIRT1 inhibitor Ex-527 (0.1 μM, the tumor cell model was used to select the dose [31]) to investigate whether SIRT1 activation mediated the therapeutic effect of UA on cancer cachexia and evaluated its effects on myotube atrophy in vitro.